Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Capital Expenditures (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Capital Expenditures for 12 consecutive years, with $190000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures changed N/A to $190000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $241000.0, a 77.69% decrease, with the full-year FY2024 number at $332000.0, down 86.66% from a year prior.
  • Capital Expenditures was $190000.0 for Q4 2024 at Theravance Biopharma, up from $15000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.4 million in Q2 2020 to a low of -$57000.0 in Q3 2022.
  • A 5-year average of $730357.1 and a median of $258000.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: skyrocketed 2562.34% in 2020, then tumbled 90.3% in 2024.
  • Theravance Biopharma's Capital Expenditures stood at $1.2 million in 2020, then surged by 42.04% to $1.8 million in 2021, then tumbled by 84.95% to $266000.0 in 2022, then soared by 252.63% to $938000.0 in 2023, then plummeted by 79.74% to $190000.0 in 2024.
  • Per Business Quant, the three most recent readings for TBPH's Capital Expenditures are $190000.0 (Q4 2024), $15000.0 (Q3 2024), and $36000.0 (Q2 2024).